Introduction
Drug-induced liver disease is a common clinical problem. Up to 25% of cases of fulminant hepatic failure may be the result of adverse reactions to drugs. 1,2 For certain drugs such as isoniazid, chlorpromazine and methyldopa minor abnormalities in liver function tests can be detected in up to 20% of asymptomatic patients during therapy.3 These patients have minimal nonspecific focal hepatitis on liver biopsy often associated with both portal and intralobular inflammation. In addition it is estimated that approximately 2% ofjaundiced patients admitted to general hospitals have drug-induced liver disease.'
In geriatric facilities the incidence may be 10-fold higher. ' The susceptibility of the liver to damage by drugs is a consequence ofits primary role in drug metabolism. 5 As the vast array ofchemicals to which we are exposed expands and the number ofimplicated agents continue to increase, awareness of drug-induced liver disease is important in all areas of clinical medicine. Recognition of a drug aetiology is essential since the prognosis is generally good upon withdrawal.
We report on the clinical, aetiological and histological features of acute drug-induced liver disease seen at the University Hospital, Jamaica, over a 15 year period.
Patients and methods
Patients admitted to the University Hospital, Kingston, Jamaica with drug-induced liver disease in the The clinical presenting features, biochemical abnormalities, drug intake and outcome were studied. The histological details of all liver biopsy specimens were also reviewed. The histological classification used is modified from that proposed by Zimmerman and Ishak,6 for drug-induced hepatic injury. The biochemical abnormalities recorded were the initial or the highest value obtained.
Criteria for inclusion in the study were: (1) presence of jaundice and/or abnormal liver-related liver enzymes temporally related to (2) recent drug exposure, (3) absence of known previous underlying liver disease, (4) compatible hepatic histological findings and (5) improvement of abnormal clinical and biochemical parameters on withdrawal of the offending drug.
Patients with alcoholic liver disease, viral hepatitis, gall stones or evidence of extrahepatic biliary obstruction were excluded.
Results
There were 53 patients with drug-induced hepatic damage who satisfied at least four of the above criteria. The mean age at presentation was 41 years (median, 40 years; range Twenty two drugs were implicated in inducing liver injury (Table III) . However, methyldopa (8) , chlorpropamide (8) , chlorpromazine (7) , halothane (5) and the oral contraceptive pill (4) There are broad histological categories that relate to the morphology of drug-induced liver injury. Acute injury may be either cholestatic or cytotoxic, the latter manifesting virtually any of the morphological lesions known in hepatology. Diffuse massive or zonal necrosis may occur, accompanied by degeneration and steatosis. Cholestatic injury may be either canalicular (bland) or hepatocanalicular, when there is associated portal tract inflammation. 6 Accordingly, the whole spectrum of acute and chronic hepatocellular injury may be reproduced by drugs. Nevertheless, there are certain histological features which invariably point to drug-related injury. Linear or patchy, well defined necrosis, abundant eosinophils, large mononuclear phagocytes, bile duct injury, steatosis and non-caseating granulomas are frequent accompaniments to the general histological picture. However, there is significant overlap between these reactions and those produced by viral hepatitis and mechanical large duct biliary tract obstruction. '4 Final proof of an association between a drug and liver injury can only be established by epidemiological studies and rechallenge in an individual patient. However, in only a very few instances have patients been rechallenged with a drug.'5 Death has been reported after rechallenge or when the drug was continued in the presence of symptoms.9 Rechallenge is therefore ethically unjustifiable.8 Consequently, validation of drug-induced hepatotoxicity depends on historical, clinical, biochemical and pathological data.'6 In our patients there was no history of previous or underlying liver disease, the hepatic abnormality developed in temporal relationship to drug administration and in the majority complete clinical and biochemical recovery occurred on drug withdrawal.
Seventy two per cent of patients in this series had a predominant cholestatic reaction. This is in keeping with a compilation of adverse effects of drugs on the liver which revealed that cholestatic drug reactions were much more common than other manifestations such as hepatic necrosis. '7 In our patients the biochemical results did not correlate with the histological pattern in some patients. This indicates the unreliability of routine serum liver related enzymes in indicating a specific histological pattern. The serum enzymes are indirect tests which are useful in the initial screening and as a crude guide to the possible hepatic pattern of injury. They may also serve as a transition to more specific diagnostic tests and as markers to be followed over long periods of time. '8 A number of factors affect susceptibility to druginduced hepatic injury. However, the mechanisms by which susceptibility is increased are poorly understood. A female predominance of drug-induced injury is reported by several authors.89"8"9 Age may be another factor as drug-induced liver injury tends to occur in older patients.4 In the present series, there was no patient under 9 years, and the number of patients increased with age, with the majority being women.
Drug reactions may be predictable (dose dependent) or unpredictable (dose independent). The majority of drug reactions fall into the latter category. 3 The mechanism of drug-induced injury is uncertain but various mechanisms including hypersensitivity and genetic or acquired metabolic variation have been invoked.' Certain drug reactions are accompanied by features that suggest the involvement of immunological mechanisms. These include fever, skin rashes, arthralgia, eosinophilia and autoantibodies. It is thought that in most instances, toxic drug metabolites or the immune responses to these metabolites mediate the damage.5 Selective impairment of certain vital cellular functions may result in lethal injury to hepatocytes, whereas selective impairment to the bile secretory apparatus may result in cholestasis. 20 In conclusion, the physician must consider a drugrelated aetiology in patients presenting with evidence of hepatic disease whatever the clinical picture. This is especially important in middle aged or elderly patients. In such situations it is imperative to obtain a detailed and accurate drug history as discontinuation of the offending drug will lead to improvement in the majority.
